JPH06507182A - Ｎ−スルホニル−２−オキソインドール誘導体、それらの製造、及びそれらが存在する薬学的組成物 - Google Patents

Ｎ−スルホニル−２−オキソインドール誘導体、それらの製造、及びそれらが存在する薬学的組成物

Info

Publication number
JPH06507182A
JPH06507182A JP5512992A JP51299293A JPH06507182A JP H06507182 A JPH06507182 A JP H06507182A JP 5512992 A JP5512992 A JP 5512992A JP 51299293 A JP51299293 A JP 51299293A JP H06507182 A JPH06507182 A JP H06507182A
Authority
JP
Japan
Prior art keywords
alkyl
compound
substituted
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5512992A
Other languages
English (en)
Japanese (ja)
Inventor
フロン、ロイ
ガルシア、ジョルジュ
ニサト、ディノ
ルクス、リシャール
セラデイユーレガール、クロディーヌ
バレッテ、ゲラール
ワグノン、ジャン
Original Assignee
エルフ・サノフィ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エルフ・サノフィ filed Critical エルフ・サノフィ
Publication of JPH06507182A publication Critical patent/JPH06507182A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • C07D209/92—Naphthostyrils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP5512992A 1992-01-30 1993-01-28 Ｎ−スルホニル−２−オキソインドール誘導体、それらの製造、及びそれらが存在する薬学的組成物 Pending JPH06507182A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR92/01034 1992-01-30
FR9201034A FR2686878B1 (fr) 1992-01-30 1992-01-30 Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
PCT/FR1993/000093 WO1993015051A1 (fr) 1992-01-30 1993-01-28 Derives du n-sulfonyl-2-oxoindole ayant une affinite pour les recepteurs de la vasopressine et/ou de l'ocytocine

Publications (1)

Publication Number Publication Date
JPH06507182A true JPH06507182A (ja) 1994-08-11

Family

ID=9426168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5512992A Pending JPH06507182A (ja) 1992-01-30 1993-01-28 Ｎ−スルホニル−２−オキソインドール誘導体、それらの製造、及びそれらが存在する薬学的組成物

Country Status (20)

Country Link
EP (1) EP0581939B1 (cg-RX-API-DMAC10.html)
JP (1) JPH06507182A (cg-RX-API-DMAC10.html)
AT (1) ATE180773T1 (cg-RX-API-DMAC10.html)
AU (1) AU662960B2 (cg-RX-API-DMAC10.html)
BR (1) BR9303993A (cg-RX-API-DMAC10.html)
CA (1) CA2107348A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ203793A3 (cg-RX-API-DMAC10.html)
DE (1) DE69325130D1 (cg-RX-API-DMAC10.html)
FI (2) FI980341A0 (cg-RX-API-DMAC10.html)
FR (1) FR2686878B1 (cg-RX-API-DMAC10.html)
HU (1) HUT68642A (cg-RX-API-DMAC10.html)
IL (1) IL104559A0 (cg-RX-API-DMAC10.html)
MX (1) MX9300498A (cg-RX-API-DMAC10.html)
NO (1) NO180538C (cg-RX-API-DMAC10.html)
NZ (1) NZ249158A (cg-RX-API-DMAC10.html)
RU (1) RU2135469C1 (cg-RX-API-DMAC10.html)
SK (1) SK105393A3 (cg-RX-API-DMAC10.html)
TW (1) TW239126B (cg-RX-API-DMAC10.html)
WO (1) WO1993015051A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA93649B (cg-RX-API-DMAC10.html)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006080574A1 (ja) * 2005-01-28 2006-08-03 Taisho Pharmaceutical Co., Ltd. １，３－ジヒドロ－２ｈ－インドール－２－オン化合物、及び芳香族複素環が縮合したピロリジン－２－オン化合物
JP2008534460A (ja) * 2005-03-24 2008-08-28 アボット ゲーエムベーハー ウント カンパニー カーゲー 置換オキシインドール誘導体、それを含む医薬品およびそれの使用
JP2010504351A (ja) * 2006-09-22 2010-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バソプレッシン拮抗薬として使用されるスピロベンズアゼピン類
JP2010504352A (ja) * 2006-09-22 2010-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バソプレッシン拮抗薬としてのスピロベンズアゼピン類
JP2010512374A (ja) * 2006-12-12 2010-04-22 サノフイ−アベンテイス ５−アルキルオキシ−インドリン−２−オン誘導体、これらの調製およびｖ２バソプレシン受容体の選択的リガンドとしての治療におけるこれらの応用
JP2011507931A (ja) * 2007-12-27 2011-03-10 アボット ゲーエムベーハー ウント カンパニー カーゲー 置換オキシインドール誘導体およびこれらのバソプレシン依存性疾病の治療用の使用
JP2011518213A (ja) * 2008-04-21 2011-06-23 サノフイ−アベンテイス １，３−ジヒドロ−２Ｈ−ピロロ［３，２−ｂ］ピリジン−２−オン誘導体、この調製、およびこの治療用途

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2708608B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
FR2722190B1 (fr) * 1994-07-05 1996-10-04 Sanofi Sa Derives de 1-benzyl-1,3-dihydro-2h-benzimidazol-2-one, leur preparation, les compositions pharmaceutique en contenant
US5728712A (en) * 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
FR2740136B1 (fr) * 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
US5756497A (en) * 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
ATE264330T1 (de) 1999-07-21 2004-04-15 Astrazeneca Ab Verbindungen
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
US7186745B2 (en) 2001-03-06 2007-03-06 Astrazeneca Ab Indolone derivatives having vascular damaging activity
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
DE10222034A1 (de) * 2002-05-17 2003-11-27 Bayer Ag Tetrahydroisochinolin-Derivate
JP4473120B2 (ja) * 2002-06-21 2010-06-02 スベン ライフ サイエンシズ リミティド 治療薬剤として有用なセロトニン受容体親和性を有するアリールスルホニル・インドール、その製造方法、並びにそれらを含む医薬組成物
RU2259999C2 (ru) * 2003-08-26 2005-09-10 ООО "Исследовательский институт химического разнообразия" 1-сульфонил-1,3-дигидроиндол-2-оны, фармацевтические композиции (варианты), способ их получения и применения
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
EP1831197A2 (de) * 2004-12-31 2007-09-12 Abbott GmbH & Co. KG Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
DE102005014936A1 (de) 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
JP2008534461A (ja) 2005-03-24 2008-08-28 アボット ゲーエムベーハー ウント カンパニー カーゲー 置換オキシインドール誘導体、前記誘導体を含む医薬およびそれの使用
DE102005015957A1 (de) * 2005-03-31 2006-10-05 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
WO2007028638A1 (en) 2005-09-09 2007-03-15 Euro-Celtique S.A. Fused and spirocycle compounds and the use thereof
EP1957480A1 (de) 2005-12-02 2008-08-20 Abbott GmbH & Co. KG Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
CA2661870C (en) 2006-08-26 2014-11-18 Abbott Gmbh & Co. Kg Substituted benzimidazolone derivatives, medicaments comprising them and their use for treating vasopressin-dependent disease
DE102006040915A1 (de) 2006-08-26 2008-03-20 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
RU2009117642A (ru) 2006-10-12 2010-11-20 Ксенон Фармасьютикалз Инк. (Ca) Применение спирооксиндоловых соединений в качестве терапевтических средств
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
WO2009071690A2 (de) 2007-12-07 2009-06-11 Abbott Gmbh & Co. Kg 5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
MX2010006202A (es) 2007-12-07 2011-03-04 Abbott Gmbh & Co Kg Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
CA2707669C (en) 2007-12-07 2016-07-05 Wilfried Braje 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
FR2927625B1 (fr) * 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
HRP20150882T1 (hr) 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010138600A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
NZ599334A (en) 2009-10-14 2014-03-28 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
CN102946859B (zh) 2010-02-26 2016-03-02 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
EP2881391A1 (en) 2013-12-05 2015-06-10 Bayer Pharma Aktiengesellschaft Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
CN108698991B (zh) * 2016-01-20 2022-08-23 凯莫森特里克斯股份有限公司 2-氧代吲哚化合物
CN114702448A (zh) * 2021-09-30 2022-07-05 西南大学 环烯烃的三氟甲基化串联环化螺环化合物的合成方法
CN119019312B (zh) * 2024-10-24 2025-01-28 苏州宜联生物医药有限公司 一种吲哚-2-酮衍生物、其抗体药物偶联物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2540057A (en) 1947-07-02 1951-01-30 Gen Aniline & Film Corp Aromatic and heterocyclic diazosulfones
US3838167A (en) * 1972-08-01 1974-09-24 Lilly Co Eli Process for preparing indoles
DK167393B1 (da) 1985-12-30 1993-10-25 Roussel Uclaf 1-sulfonyl-2-oxo-pyrrolidinderivater, deres fremstilling og farmaceutiske praeparater med indhold deraf
US4863437A (en) * 1986-03-20 1989-09-05 Clarke Ellis W Means for fluid administration
US4803217A (en) * 1986-12-24 1989-02-07 Merck & Co., Inc. Hapalindolinone compounds as vassopressin antagonists
EP0303418A3 (en) * 1987-08-11 1990-11-07 Smithkline Beecham Laboratoires Pharmaceutiques Substituted indolones, useful in the treatment of heart or asthmatic diseases
DK0429685T3 (da) * 1989-07-25 1997-12-15 Taiho Pharmaceutical Co Ltd Oxoindolderivat

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006080574A1 (ja) * 2005-01-28 2006-08-03 Taisho Pharmaceutical Co., Ltd. １，３－ジヒドロ－２ｈ－インドール－２－オン化合物、及び芳香族複素環が縮合したピロリジン－２－オン化合物
US8030499B2 (en) 2005-01-28 2011-10-04 Taisho Pharmaceutical Co., Ltd. 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle
JP5125501B2 (ja) * 2005-01-28 2013-01-23 大正製薬株式会社 １，３−ジヒドロ−２ｈ−インドール−２−オン化合物、及び芳香族複素環が縮合したピロリジン−２−オン化合物
JP2008534460A (ja) * 2005-03-24 2008-08-28 アボット ゲーエムベーハー ウント カンパニー カーゲー 置換オキシインドール誘導体、それを含む医薬品およびそれの使用
JP2010504351A (ja) * 2006-09-22 2010-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バソプレッシン拮抗薬として使用されるスピロベンズアゼピン類
JP2010504352A (ja) * 2006-09-22 2010-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バソプレッシン拮抗薬としてのスピロベンズアゼピン類
JP2010512374A (ja) * 2006-12-12 2010-04-22 サノフイ−アベンテイス ５−アルキルオキシ−インドリン−２−オン誘導体、これらの調製およびｖ２バソプレシン受容体の選択的リガンドとしての治療におけるこれらの応用
JP2011507931A (ja) * 2007-12-27 2011-03-10 アボット ゲーエムベーハー ウント カンパニー カーゲー 置換オキシインドール誘導体およびこれらのバソプレシン依存性疾病の治療用の使用
JP2011518213A (ja) * 2008-04-21 2011-06-23 サノフイ−アベンテイス １，３−ジヒドロ−２Ｈ−ピロロ［３，２−ｂ］ピリジン−２−オン誘導体、この調製、およびこの治療用途

Also Published As

Publication number Publication date
EP0581939B1 (fr) 1999-06-02
WO1993015051A1 (fr) 1993-08-05
NO933482D0 (no) 1993-09-29
NO180538C (no) 1997-05-07
BR9303993A (pt) 1994-08-02
HUT68642A (en) 1995-07-28
HU9302762D0 (en) 1993-12-28
NO933482L (no) 1993-11-29
ZA93649B (en) 1993-09-02
FI980341A7 (fi) 1998-02-13
FI934274A7 (fi) 1993-09-29
NZ249158A (en) 1996-02-27
FR2686878B1 (fr) 1995-06-30
CA2107348A1 (en) 1993-07-31
FI980341L (fi) 1998-02-13
TW239126B (cg-RX-API-DMAC10.html) 1995-01-21
RU2135469C1 (ru) 1999-08-27
AU662960B2 (en) 1995-09-21
FR2686878A1 (fr) 1993-08-06
CZ203793A3 (en) 1994-04-13
FI980341A0 (fi) 1998-02-13
SK105393A3 (en) 1994-08-10
EP0581939A1 (fr) 1994-02-09
ATE180773T1 (de) 1999-06-15
FI934274A0 (fi) 1993-09-29
FI934274L (fi) 1993-09-29
AU3504393A (en) 1993-09-01
IL104559A0 (en) 1993-05-13
MX9300498A (es) 1994-07-29
NO180538B (no) 1997-01-27
DE69325130D1 (de) 1999-07-08

Similar Documents

Publication Publication Date Title
JPH06507182A (ja) Ｎ−スルホニル−２−オキソインドール誘導体、それらの製造、及びそれらが存在する薬学的組成物
EP0950047B1 (fr) Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
EP0873309B1 (fr) Derives 3-spiro-indolin-2-one comme ligands des recepteurs de la vasopressine et/ou de l'ocytocine
US5585394A (en) 1-benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one derivatives
EP0687251B1 (fr) Derives de 1,3-dihydroindol-2-one substitues en 3 par un groupe azote comme agonistes et/ou antagonistes de la vasopressine et/ou de l'ocytocine
RU2141476C1 (ru) Производные 1-бензолсульфонил-1,3-дигидро-индол-2-она, способ их получения и содержащие их фармацевтические композиции
SK404091A3 (en) Indole derivatives, method of production and pharmaceutical agents containing them
EP0636609A1 (fr) Dérivés du 1-benzyl-1,3-dihydro-indol-2-one, leur préparation, les compositions pharmaceutiques en contenant
FR2722190A1 (fr) Derives de 1-benzyl-1,3-dihydro-2h-benzimidazol-2-one, leur preparation, les compositions pharmaceutique en contenant
US4351770A (en) Preparation of N(2-pyrrolidinylmethyl)2-methoxy-5-benzenesulfonamidobenzamides
US4180581A (en) N-9,10-dihydrolysergyl-m-aminobenzoic acid amide derivative
JP3898219B2 (ja) フエニルインドール化合物
HK1016596B (en) 3-spiro-indolin-2-one derivatives as vasopressin and/or oxytocin receptor ligands